Category - Developments

Developments

resTORbio reports new Phase 2b data for respiratory tract infection candidate

resTORbio (NASDAQ:TORC) reported new data from its Phase 2b trial of RTB101 for the treatment of respiratory tract infections (RTIs) in patients 65 years of age and older. Licensed from Novartis, RTB101 is a TORC1...

May 21, 2019

Developments

Axovant doses first patient in gangliosidosis gene therapy trial

Axovant Gene Therapies (NASDAQ:AXGT) has dosed the first patient in a clinical study of AXO-AAV-GM1 for the treatment of GM1 gangliosidosis. GM1 gangliosidosis is a rare genetic disease where mutations in the GLB1 gene...

May 17, 2019

Developments

Mustang Bio gets FDA orphan drug designation for malignant glioma

Mustang Bio (NASDAQ:MBIO) and development partner, Nationwide Children’s Hospital (NCH), received FDA orphan drug designation for MB-108 for the treatment of malignant glioma. Malignant glioma is a type of brain cancer...

May 17, 2019

Developments

Achillion reports positive interim Phase 2 data in paroxysmal nocturnal hemoglobinuria

Achillion Pharmaceuticals (NASDAQ:ACHN) reported interim data from its Phase 2 trial of ACH-4471, in combination with eculizumab, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). In PNH, the complement...

May 17, 2019

Developments

Abstracts for BeyondSpring Plinabulin-Neulasta combination accepted at ASCO

Two of BeyondSpring’s (NASDAQ:BYSI) abstracts about its lead asset, Plinabulin, were accepted for publication in the proceedings of this year’s ASCO annual meeting May 31 to June 4 in Chicago. The data, derived from...

May 16, 2019

Developments

MacroGenics reports positive Phase 3 results in HER2-positive metastatic breast cancer

MacroGenics’ (NASDAQ:MGNX) Phase 3 trial of margetuximab met its first sequential primary endpoint of progression-free survival (PFS) in patients with HER2-positive metastatic breast cancer. The median PFS of patients...

May 16, 2019

Developments

FDA accepts Cue Biopharma IND for HPV-associated cancer candidate

Cue Biopharma’s (NASDAQ:CUE) IND for CUE-101, an immuno-oncology candidate for human papilloma virus (HPV)-associated cancers, had been accepted by the FDA. The majority of HPV-associated cancers are caused by the HPV16...

May 16, 2019

Developments

Rigel Pharma enrolls first patient in Phase 3 autoimmune hemolytic anemia trial

Rigel Pharmaceuticals (NASDAQ:RIGL) enrolled the first patient in its pivotal Phase 3 trial of fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia (AIHA).

May 16, 2019

Developments

Ceapro receives site license from Health Canada

Ceapro’s (TSXV:CZO) two bioprocessing plants in Alberta received a site license from the Health Canada Natural and Non-Prescription Health Products Directorate, which enables the company to fabricate, package, label...

May 15, 2019

Developments

Principia Biopharma doses first patient in Phase 2b MS trial

Principia Biopharma (NASDAQ:PRNB) has dosed the first patient in its Phase 2b clinical trial of SAR442168 in patients with relapsing multiple sclerosis (MS). Neuroinflammation and an increase in the number of B cells in...

May 15, 2019

Category - Developments

Subscribe